Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Diagnostic & Testing Equipment
- Sub-Industry: N/A
- Symbol: NASDAQ:OXFD
- CUSIP: N/A
- Web: www.oxfordimmunotec.com
Capitalization:- Market Cap: $373.94 million
- Outstanding Shares: 22,926,000
Average Prices:- 50 Day Moving Avg: $15.71
- 200 Day Moving Avg: $14.80
- 52 Week Range: $7.73 - $17.38
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -20.91
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $90.47 million
- Price / Sales: 4.13
- Book Value: $2.92 per share
- Price / Book: 5.59
Profitability:- EBIDTA: ($22,950,000.00)
- Net Margins: -25.83%
- Return on Equity: -31.48%
- Return on Assets: -22.01%
Debt:- Debt-to-Equity Ratio: 0.45%
- Current Ratio: 4.00%
- Quick Ratio: 3.54%
Misc:- Average Volume: 86,664 shs.
- Beta: -0.12
- Short Ratio: 4.91
Frequently Asked Questions for Oxford Immunotec Global PLC (NASDAQ:OXFD)
What is Oxford Immunotec Global PLC's stock symbol?
Oxford Immunotec Global PLC trades on the NASDAQ under the ticker symbol "OXFD."
How were Oxford Immunotec Global PLC's earnings last quarter?
Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its earnings results on Tuesday, May, 2nd. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.01. The company earned $21.51 million during the quarter, compared to analyst estimates of $21.17 million. Oxford Immunotec Global PLC had a negative net margin of 25.83% and a negative return on equity of 31.48%. View Oxford Immunotec Global PLC's Earnings History.
Where is Oxford Immunotec Global PLC's stock going? Where will Oxford Immunotec Global PLC's stock price be in 2017?
1 equities research analysts have issued 1 year target prices for Oxford Immunotec Global PLC's shares. Their forecasts range from $19.00 to $19.00. On average, they expect Oxford Immunotec Global PLC's stock price to reach $19.00 in the next year. View Analyst Ratings for Oxford Immunotec Global PLC.
What are analysts saying about Oxford Immunotec Global PLC stock?
Here are some recent quotes from research analysts about Oxford Immunotec Global PLC stock:
- 1. BTIG Research analysts commented, "This evening bluebird provided a 1Q update via press release (no conference call, as usual). Following an April meeting with the EMA, BLUE updated its EU regulatory strategy noting that it anticipates filing for conditional approval in non-B0/B0 patients on the basis of the ongoing Northstar and HGB-205 studies, plus data available from the ongoing Northstar-2 at the time of filing. Amount of follow up needed from Northstar and HGB-205 is TBD (data dependent and discussions with the EMA are ongoing). On the catalyst front, previously announced timelines are intact, and 2017 is looking to be a busy year for bluebird. Overall, we remain encouraged with the company’s continued progress across multiple clinical programs involving its potentially transformative gene therapy and CAR-T platforms. Maintain OW." (5/4/2017)
- 2. According to Zacks Investment Research, "Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company's first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. " (5/3/2017)
Who are some of Oxford Immunotec Global PLC's key competitors?
Some companies that are related to Oxford Immunotec Global PLC include La Jolla Pharmaceutical Company (LJPC), Vanda Pharmaceuticals (VNDA), NeoGenomics (NEO), Revance Therapeutics (RVNC), Enanta Pharmaceuticals (ENTA), Civitas Solutions (CIVI), Heska Corporation (HSKA), Cytokinetics, Incorporated (CYTK), Anika Therapeutics (ANIK), Lantheus Holdings (LNTH), Sangamo Therapeutics (SGMO), Novadaq Technologies (NVDQ), AMAG Pharmaceuticals (AMAG), CRISPR THERAPTC (CRSP), Depomed (DEPO), Mesoblast Limited (MESO), Editas Medicine (EDIT) and Spectrum Pharmaceuticals (SPPI).
Who are Oxford Immunotec Global PLC's key executives?
Oxford Immunotec Global PLC's management team includes the folowing people:
- Richard A. Sandberg, Independent Chairman of the Board
- Peter Wrighton-Smith Ph.D., Chief Executive Officer, Director
- Richard M. Altieri, Chief Financial Officer
- Peter Edwardson Ph.D., Chief Operating Officer
- Stephen M. Gansler, Senior Vice President and Global Head of Human Resources
- Elizabeth M. Keiley, Vice President, General Counsel
- Jeff R. Schroeder, Chief Commercial Officer
- .. Scott .., Director
- Ronald A. Andrews Jr., Director
- Patrick J. Balthrop Sr., Director
Who owns Oxford Immunotec Global PLC stock?
Oxford Immunotec Global PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.05%). Company insiders that own Oxford Immunotec Global PLC stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global PLC.
How do I buy Oxford Immunotec Global PLC stock?
Shares of Oxford Immunotec Global PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oxford Immunotec Global PLC's stock price today?
One share of Oxford Immunotec Global PLC stock can currently be purchased for approximately $16.31.
MarketBeat Community Rating for Oxford Immunotec Global PLC (NASDAQ OXFD)MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Oxford Immunotec Global PLC (NASDAQ:OXFD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $19.00 (16.49% upside) |
Analysts' Ratings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/4/2017 | BTIG Research | Reiterated Rating | Buy | | Medium |  |
| 6/26/2016 | Piper Jaffray Companies | Reiterated Rating | Buy | | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for Oxford Immunotec Global PLC (NASDAQ:OXFD)Earnings History by Quarter for Oxford Immunotec Global PLC (NASDAQ OXFD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/2/2017 | 3/31/2017 | ($0.35) | ($0.36) | $21.17 million | $21.51 million | View | Listen | |
| 3/1/2017 | 12/31/2016 | ($0.39) | ($0.22) | $23.06 million | $23.71 million | View | Listen | |
| 11/1/2016 | Q316 | ($0.33) | ($0.18) | $24.79 million | $26.10 million | View | N/A | |
| 8/2/2016 | Q216 | ($0.33) | ($0.29) | $18.10 million | $19.20 million | View | N/A | |
| 5/3/2016 | Q116 | ($0.32) | ($0.32) | $16.96 million | $17.10 million | View | N/A | |
| 3/1/2016 | Q415 | ($0.28) | ($0.29) | $16.34 million | $16.00 million | View | N/A | |
| 11/3/2015 | Q315 | ($0.25) | ($0.20) | $17.31 million | $17.90 million | View | N/A | |
| 8/4/2015 | Q215 | ($0.34) | ($0.33) | $14.04 million | $14.30 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.33) | ($0.31) | $13.35 million | $13.80 million | View | N/A | |
| 3/3/2015 | Q414 | ($0.44) | ($0.39) | $11.93 million | $12.10 million | View | N/A | |
| 11/4/2014 | Q314 | ($0.38) | ($0.35) | $12.85 million | $13.30 million | View | N/A | |
| 8/5/2014 | Q214 | ($0.20) | ($0.36) | $11.39 million | $11.80 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.18) | ($0.18) | $11.64 million | $12.30 million | View | N/A | |
| 3/4/2014 | Q413 | ($0.19) | ($0.38) | $9.28 million | $10.20 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Oxford Immunotec Global PLC (NASDAQ:OXFD)Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-0.78 EPS
Dividend History for Oxford Immunotec Global PLC (NASDAQ:OXFD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oxford Immunotec Global PLC (NASDAQ:OXFD)Insider Ownership Percentage: 7.58%
Institutional Ownership Percentage: 87.53%
Insider Trades by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/6/2017 | Peter Wrighton-Smith | CEO | Sell | 27,168 | $15.94 | $433,057.92 | |
| 7/5/2017 | Peter Wrighton-Smith | CEO | Sell | 32,832 | $16.58 | $544,354.56 | |
| 6/28/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $16.06 | $481,800.00 | |
| 6/15/2017 | Elizabeth M Keiley | VP | Sell | 4,085 | $15.01 | $61,315.85 | |
| 5/15/2017 | Peter Edwardson | COO | Sell | 10,000 | $14.66 | $146,600.00 | |
| 5/10/2017 | Richard A Sandberg | Director | Sell | 3,000 | $14.40 | $43,200.00 | |
| 5/9/2017 | Jeff R Schroeder | Insider | Sell | 40,000 | $14.14 | $565,600.00 | |
| 4/3/2017 | Peter Wrighton-Smith | CEO | Sell | 30,000 | $15.43 | $462,900.00 | |
| 4/3/2017 | Richard A Sandberg | Director | Sell | 3,000 | $15.47 | $46,410.00 | |
| 3/20/2017 | Elizabeth M Keiley | VP | Sell | 3,000 | $16.05 | $48,150.00 | |
| 2/6/2017 | Peter Wrighton-Smith | CEO | Sell | 25,000 | $13.36 | $334,000.00 | |
| 12/16/2016 | Peter Wrighton-Smith | CEO | Sell | 7,052 | $15.07 | $106,273.64 | |
| 12/5/2016 | Peter Wrighton-Smith | CEO | Sell | 1,140 | $15.00 | $17,100.00 | |
| 12/2/2016 | Peter Wrighton-Smith | CEO | Sell | 61,808 | $15.00 | $927,120.00 | |
| 11/8/2016 | Richard A Sandberg | Director | Sell | 12,000 | $14.17 | $170,040.00 | |
| 11/18/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.48 | $67,400.00 | |
| 11/17/2015 | Richard A. Sandberg | Director | Sell | 5,000 | $13.00 | $65,000.00 | |
| 6/16/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 41,230 | $14.30 | $589,589.00 | |
| 6/15/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 1,529 | $14.27 | $21,818.83 | |
| 6/12/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 31,598 | $14.27 | $450,903.46 | |
| 6/10/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 24,649 | $14.28 | $351,987.72 | |
| 6/9/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 13,000 | $14.26 | $185,380.00 | |
| 6/8/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 2,662 | $14.25 | $37,933.50 | |
| 6/3/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 36,474 | $14.29 | $521,213.46 | |
| 6/1/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.14 | $42,420.00 | |
| 3/23/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 53,415 | $14.49 | $773,983.35 | |
| 3/19/2015 | Lifesciences I L.P. Clarus | Major Shareholder | Sell | 154,319 | $14.65 | $2,260,773.35 | |
| 1/14/2015 | Richard A Sandberg | Director | Sell | 3,000 | $14.00 | $42,000.00 | |
| 12/5/2014 | Patricia Randall | Director | Sell | 5,000 | $12.06 | $60,300.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Oxford Immunotec Global PLC (NASDAQ:OXFD)
Latest Headlines for Oxford Immunotec Global PLC (NASDAQ:OXFD)
| Source: |
|
| Date | Headline |
|---|
 | Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.30 Million
www.americanbankingnews.com - July 22 at 8:50 AM |
| -$0.32 EPS Expected for Oxford Immunotec Global PLC (NASDAQ:OXFD) This Quarter
www.americanbankingnews.com - July 20 at 6:24 PM |
 | Oxford Immunotec Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017
finance.yahoo.com - July 19 at 1:31 AM |
| Comparing WaferGen Bio-systems (WGBS) & Oxford Immunotec Global PLC (NASDAQ:OXFD)
www.americanbankingnews.com - July 16 at 10:28 PM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $433,057.92 in Stock
www.americanbankingnews.com - July 10 at 8:13 PM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $544,354.56 in Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
| Analyzing HTG Molecular Diagnostics (HTGM) & Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - July 6 at 12:32 AM |
| Oxford Immunotec Global PLC (OXFD) CEO Sells $481,800.00 in Stock
www.americanbankingnews.com - June 29 at 7:48 PM |
| $25.33 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - June 28 at 10:52 AM |
| Oxford Immunotec Global PLC (OXFD) Expected to Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - June 26 at 4:12 PM |
 | Oxford Immunotec: Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France
www.finanznachrichten.de - June 23 at 8:52 AM |
| Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France
finance.yahoo.com - June 23 at 8:52 AM |
| Contrasting Oxford Immunotec Global PLC (OXFD) & Myriad Genetics (MYGN)
www.americanbankingnews.com - June 23 at 8:16 AM |
| Oxford Immunotec Global PLC (OXFD) VP Elizabeth M. Keiley Sells 4,085 Shares
www.americanbankingnews.com - June 16 at 7:58 PM |
| Zacks: Oxford Immunotec Global PLC (OXFD) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - June 16 at 10:30 AM |
| ETFs with exposure to Oxford Immunotec Global Plc : June 15, 2017
finance.yahoo.com - June 16 at 8:36 AM |
| Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
finance.yahoo.com - June 16 at 8:36 AM |
| Oxford Immunotec Global Plc breached its 50 day moving average in a Bullish Manner : OXFD-US : June 16, 2017
finance.yahoo.com - June 16 at 8:36 AM |
| Analyzing SurModics (SRDX) and Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - June 11 at 8:26 AM |
| Oxford Immunotec Global Plc – Value Analysis (NASDAQ:OXFD) : June 6, 2017
finance.yahoo.com - June 6 at 7:55 PM |
| Oxford Immunotec Global Plc breached its 50 day moving average in a Bullish Manner : OXFD-US : June 5, 2017
finance.yahoo.com - June 5 at 7:44 PM |
 | Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations
feeds.benzinga.com - June 5 at 8:22 AM |
| Oxford Immunotec Global PLC (OXFD) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - June 3 at 6:58 PM |
| Oxford Immunotec Global PLC (OXFD) Expected to Announce Quarterly Sales of $25.33 Million
www.americanbankingnews.com - June 2 at 1:48 PM |
| Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - May 31 at 12:48 PM |
| ETFs with exposure to Oxford Immunotec Global Plc : May 26, 2017
finance.yahoo.com - May 26 at 8:16 PM |
| Peter Edwardson Sells 10,000 Shares of Oxford Immunotec Global PLC (OXFD) Stock
www.americanbankingnews.com - May 16 at 7:53 PM |
| Insider Selling: Oxford Immunotec Global PLC (OXFD) Director Sells 3,000 Shares of Stock
www.americanbankingnews.com - May 11 at 8:48 PM |
| Oxford Immunotec Global PLC (OXFD) Insider Sells $565,600.00 in Stock
www.americanbankingnews.com - May 10 at 11:03 PM |
| Zacks: Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Post Quarterly Sales of $25.35 Million
www.americanbankingnews.com - May 7 at 8:16 AM |
| ETFs with exposure to Oxford Immunotec Global Plc : May 5, 2017
finance.yahoo.com - May 5 at 7:22 PM |
| Zacks: Brokerages Anticipate Oxford Immunotec Global PLC (OXFD) to Announce -$0.28 EPS
www.americanbankingnews.com - May 5 at 12:18 PM |
| Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : May 4, 2017
finance.yahoo.com - May 4 at 7:15 PM |
| Oxford Immunotec Global Plc :OXFD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 4 at 7:15 PM |
| BTIG Research Reiterates Buy Rating for Oxford Immunotec Global PLC (OXFD)
www.americanbankingnews.com - May 4 at 3:10 PM |
| Edited Transcript of OXFD earnings conference call or presentation 2-May-17 12:00pm GMT
finance.yahoo.com - May 3 at 7:57 PM |
| Oxford Immunotec Global PLC (OXFD) Issues Earnings Results
www.americanbankingnews.com - May 3 at 6:44 PM |
| Oxford Immunotec Global PLC (OXFD) Receives Daily Media Impact Score of 0.05
www.americanbankingnews.com - May 3 at 3:30 PM |
| Investor Network: Oxford Immunotec Global PLC to Host Earnings Call
finance.yahoo.com - May 2 at 11:09 AM |
| Oxford Immunotec Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 11:09 AM |
 | Oxford Immunotec reports 1Q loss
marketbeat.com - May 2 at 7:42 AM |
| Oxford Immunotec Global PLC (OXFD) Getting Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 7:40 AM |
| Somewhat Favorable Media Coverage Very Likely to Impact Oxford Immunotec Global PLC (OXFD) Stock Price
www.americanbankingnews.com - April 24 at 9:16 PM |
| Somewhat Positive News Coverage Very Likely to Affect Oxford Immunotec Global PLC (OXFD) Share Price
www.americanbankingnews.com - April 21 at 8:11 PM |
| Oxford Immunotec Schedules First Quarter 2017 Earnings Release and Conference Call for May 2, 2017
finance.yahoo.com - April 19 at 7:07 PM |
| Oxford Immunotec Global PLC (OXFD) Earning Somewhat Critical Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 10:00 AM |
| Somewhat Positive Press Coverage Very Likely to Effect Oxford Immunotec Global PLC (OXFD) Stock Price
www.americanbankingnews.com - April 14 at 6:51 PM |
| -$0.32 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter
www.americanbankingnews.com - April 14 at 1:16 PM |
| Oxford Immunotec Global PLC (OXFD) Sees Large Increase in Short Interest
www.americanbankingnews.com - April 6 at 1:28 PM |
| Insider Selling: Oxford Immunotec Global PLC (OXFD) CEO Sells 30,000 Shares of Stock
www.americanbankingnews.com - April 5 at 8:28 PM |
Oxford Immunotec Global PLC (OXFD) Chart for Monday, July, 24, 2017
